[en] Ertugliflozin is a new sodium-glucose cotransporter type 2 inhibitor (SGLT2i) that is indicated in the treatment of type 2 diabetes. It has been investigated in the large phase 3 development programme VERTIS, in monotherapy and in association with different antidiabetic medications, including insulin. The add-on of ertugliflozin to metformin (VERTIS MET) and the association ertugliflozin-sitagliptin (VERTIS-SITA, VERTIS FACTORIAL, VERTIS SITA2) showed a significant reduction in glycated haemoglobin, without hypoglycaemia, together with a diminution of body weight and arterial blood pressure. As expected, more genital mycotic infections were observed, the only adverse event consistently reported. The cardiovascular safety of ertugliflozin has been demonstrated in VERTIS CV. Ertugliflozin is commercialized with two doses 5 mg and 15 mg. This SGLT2i is also available in fixed-dose combinations, ertugliflozin-metformin and ertugliflozin-sitagliptin. The three presentations offer a greater flexibility to the practitioner to optimize therapeutic choices for a complex disease where the treatment should be individualized according to the patient profile.
Scheen AJ, Paquot N. Extension des indications pour les antidiabétiques avec protection cardio-rénale dans les dernières recommandations internationales pour la prise en charge du patient diabétique de type 2. Rev Med Liege 2020; 75:233-9.
Scheen AJ, Paquot N. Une révolution dans le traitement du diabète de type 2 : des antidiabétiques dotés d'une protection cardio-rénale indépendamment du contrôle glycémique ! Rev Med Liege 2020; 75:392-8.
Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020 Aug 27. doi: 10.1038/s41574-020-0392-2.
Scheen AJ. Canagliflozine (Invokana®) : inhibiteur des cotransporteurs rénaux SGLT2 pour traiter le diabète de type 2. Rev Med Liege 2014; 69:692-9.
Scheen AJ. Empagliflozine (Jardiance®) : nouvel inhibiteur des cotransporteurs rénaux SGLT2 comme traitement du diabète de type 2. Rev Med Liege 2015; 70:472-9.
Scheen AJ. Dapagliflozine (Forxiga®) Inhibiteur des cotransporteurs rénaux SGLT2, nouvel agent anti-hyperglycemiant dans le diabète de type 2. Rev Med Liege 2016; 71:463-9.
Scheen AJ. A propos de l'expérience belge avec les inhibiteurs des SGLT2. Med Mal Metab 2020; 14:320-30.
Markham A. Ertugliflozin: First Global Approval. Drugs 2018; 78:513-9. 9. Fediuk DJ, Nucci G, Dawra VK, et al. Overview of the clinical pharmacology of ertugliflozin, a novel sodium-glucose cotransporter 2 (SGLT2) inhibitor. Clin Pharmacokinet 2020; 59:949-65.
Scheen AJ. Pharmacodynamics, efficacy and safety of sodiumglucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015; 75:33-59.
Scheen AJ. Drug-drug interactions with SGLT-2 inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes. Clin Pharmacokinet 2014; 53:295-304.
Scheen AJ. Combinaison fixe sitagliptine-metformine (Janumet ®). Rev Med Liege 2010; 65:648-54.
Scheen AJ. The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. Expert Opin Drug Saf 2018; 17:837-48.
Rosenstock J, Frias J, Pall D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab 2018; 20:520-9.
Gallo S, Charbonnel B, Goldman A, et al. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes Obes Metab 2019; 21:1027-36.
Frias JP. Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes. Expert Rev Endocrinol Metab 2019; 14:75-83.
Scheen AJ. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opin Drug Metab Toxicol 2016; 12:1407-17.
Scheen AJ, Paquot N. Combinaison gliptine-gliflozine dans le traitement du diabète de type 2. Rev Med Suisse 2016; 12:1384-8.
Scheen AJ, Van Gaal LF. Sitagliptine (Januvia®). Incrétinopotentiateur indiqué comme insulinosécrétagogue dans le traitement du diabète de type 2. Rev Med Liege 2008; 63:105-9.
Scheen AJ, Van Gaal LF. La sitagliptine dans le traitement du diabète de type 2 : le point cinq ans apres sa commercialisation. Rev Med Liege 2013; 68:504-10.
Scheen AJ, Paquot N. TECOS : confirmation de la sécurité cardiovasculaire de la sitagliptine. Rev Med Liege 2015; 70:511-6.
Miller S, Krumins T, Zhou H, et al. Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study. Diabetes Ther 2018; 9:253-68.
Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. Diabetes Obes Metab 2018; 20:1111-20.
Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab 2018; 20:530-40.
Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J 2018; 206:11-23.
Cannon C. VERTIS CV : cardiovascular and renal outcomes. Présentation au congrès de l'American Diabetes Association, Chicago, 16 juin 2020. https://www.acc.org/education-andmeetings/ image-and-slide-gallery/media-detail?id=307A7E10 3BC04A588A3370709253FC35.
Scheen AJ. Protection cardio-rénale avec les inhibiteurs des SGLT2 : d'EMPA-REG OUTCOME à VERTIS CV. Rev Med Suisse 2020; 16:1483-8.
Patel S, Hickman A, Frederich R, et al. Safety of ertugliflozin in patients with type 2 diabetes mellitus: pooled analysis of seven phase 3 randomized controlled trials. Diabetes Ther 2020; 11:1347-67.
Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Safety 2019; 18:295-311.
Paquot N, Scheen AJ. Ajout d'un inhibiteur de la DPP-4 ou des SGLT2 après échec d'une monothérapie par metformine chez le patient diabétique de type 2. Rev Med Suisse 2017; 13:1410-5.
Scheen AJ. Comment je traite ... un patient diabétique de type 2 mal contrôlé sous une combinaison metformine plus gliptine. Rev Med Liege 2019; 74:443-50.
Scheen AJ. Combinaison «inhibiteur des SGLT2-agoniste des récepteurs du GLP-1» pour traiter le diabète de type 2. Rev Med Suisse 2019; 15:1436-41.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
